Cardiovascular pharmacogenetics

Human genetic variation in the form of single nucleotide polymorphisms as well as more complex structural variations such as insertions, deletions and copy number variants, is partially responsible for the clinical variation seen in response to pharmacotherapeutic drugs. This affects the likelihood...

Full description

Saved in:
Bibliographic Details
Published in:Pharmacology & therapeutics (Oxford) 2012-03, Vol.133 (3), p.280-290
Main Authors: Myburgh, Renier, Hochfeld, Warren E, Dodgen, Tyren M, Ker, James, Pepper, Michael S
Format: Article
Language:English
Subjects:
Cardiovascular Agents - pharmacokinetics
Cardiovascular Agents - pharmacology
Cardiovascular Agents - therapeutic use
Cardiovascular diseases
Cardiovascular Diseases - drug therapy
Cardiovascular Diseases - genetics
Cardiovascular Diseases - metabolism
copy number
Drug development
Enzymes
Gene deletion
Genetic diversity
Humans
Insertion
Pharmacodynamics
Pharmacogenetics
Pharmacokinetics
Polymorphism, Genetic
Reviews
Single-nucleotide polymorphism
Toxicity
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Human genetic variation in the form of single nucleotide polymorphisms as well as more complex structural variations such as insertions, deletions and copy number variants, is partially responsible for the clinical variation seen in response to pharmacotherapeutic drugs. This affects the likelihood of experiencing adverse drug reactions and also of achieving therapeutic success. In this paper, we review key studies in cardiovascular pharmacogenetics that reveal genetic variations underlying the outcomes of drug treatment in cardiovascular disease. Examples of genetic associations with drug efficacy and toxicity are described, including the roles of genetic variability in pharmacokinetics (e.g. drug metabolizing enzymes) and pharmacodynamics (e.g. drug targets). These findings have functional implications that could lead to the development of genetic tests aimed at minimizing drug toxicity and optimizing drug efficacy in cardiovascular medicine.
ISSN:0163-7258
1879-016X
DOI:10.1016/j.pharmthera.2011.11.002